ClinicalTrials.gg
Not yet recruitingNCT07142187Updated Nov 17, 2026

The Clinical Trial of Electro-thumbtack Needle on Live Birth Rate in Patients With Ovarian Reserve Dysfunction (DOR)

An interventional study of electro-thumbtack needle and placebo electro-thumbtack needle in Diminished Ovarian Reserve (DOR), sponsored by Huazhong University of Science and Technology. Not yet recruiting. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Huazhong University of Science and Technology · Not applicable, Interventional, and Treatment

How we know

Updated Nov 17, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
368
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

This study will include 246 patients with ovarian reserve dysfunction (DOR), who will be randomly divided into a treatment group and a control group, with 123 patients in each group. The treatment group will receive electro-thumbtack needle treatment, while the control group will receive placebo electro-thumbtack needle treatment. Both groups will receive a treatment course of 3 menstrual cycles. This study evaluates the effect of electrocautery on the live birth rate of patients with DOR.

02

Conditions studied

  • Diminished Ovarian Reserve (DOR)
03

In context

Lead sponsor

Huazhong University of Science and Technology is the lead sponsor of 248 studies on the registry; 62 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The age range is 18-40 years old;
  • Meets the diagnostic criteria for DOR as follows: ① AMH\<1.1 ng/ml; ② 10 U/L \< FSH \< 25U/L or FSH/LH > 3.6; ③ The total number of follicles (AFC) in both basal sinuses is less than 7. If any two of the above criteria (①②③) are met, it can be diagnosed as DOR.
  • At least one side of the patient's fallopian tube is unobstructed;
  • The semen routine examination of the patient's spouse is normal;
  • Voluntarily sign the form.

Exclusion criteria

Exclusion Criteria:

  • Chromosomal or genetic abnormalities in either the female or male partner;
  • Women with blocked fallopian tubes on both sides;
  • Have a history of ovarian surgery, such as ovarian teratoma or ovarian chocolate cyst surgery;
  • The female party suffers from uncorrected endocrine disorders such as simple hyperthyroidism or hypothyroidism, hyperprolactinemia, and pancreatic islet dysfunction;
  • Hormone resistance, diabetes, adrenal diseases, etc;
  • The woman has a clearly diagnosed disease such as systemic lupus erythematosus, rheumatoid arthritis;
  • Antiphospholipid syndrome, Sjogren's syndrome, Hashimoto's thyroiditis, etc;
  • The female or male partner has a history of malignant tumors and has received treatment with radiotherapy and chemotherapy;
  • The woman has received acupuncture and moxibustion or press acupuncture treatment in recent 3 months;
  • Those who take traditional Chinese medicine decoctions or granules during treatment;
  • Men with abnormal semen examination;
  • Clear diagnosis of moderate or severe adenomyosis;
  • Clearly diagnose uterine fibroids with a diameter greater than 5cm;
  • I do not agree to sign the form for this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
368 participants (estimated)

Study arms

  • Experimental
    electro-thumbtack needle group

    Electro-thumbtack needle is a sterile needle with a special conductive chip that can conduct electricity. Electro-thumbtack needle enhances the stimulation effect on acupoints by introducing pulsed microcurrents, and is a long-lasting needle retention therapy with stronger stimulation effect than ordinary acupressure.

    Other: electro-thumbtack needle

  • Placebo comparator
    Placebo group

    Placebo electro-thumbtack needle use insulated soft silk threads instead of needle bodies, making their appearance, shape, and color no different from real electro-thumbtack needle, but without needle like effects; Placebo electro-thumbtack needle also do not have the conductivity of true electric needles (silk threads are insulated); The placebo conductive patch used in the control group, although having the same appearance as the treatment group, is a specially insulated control substance. Therefore, even if the pulse generator is turned on and adjusted to medium intensity, the patient still receives zero current stimulation intensity.

    Other: placebo electro-thumbtack needle

Interventions

  • Otherelectro-thumbtack needle

    The treatment acupoints include bilateral ovarian acupoints, Guan Yuan (CV4), bilateral Shen Shu (BL23), bilateral waist and eye acupoints (EX-B7), bilateral San Yin Jiao (SP6), and bilateral Zu San Li (ST36), totaling 11 acupoints. Among them, the bilateral ovarian acupoints and bilateral waist eye acupoints (EX-B7) were treated with electro-thumbtack needle. Other acupoints were treated with thumbtack needle.Choose a sparse and dense waveform, adjust the intensity to the maximum patient can tolerate, and stimulate for 30 minutes each time. After the stimulation is completed, remove the electrode patch and electroacupuncture device, and keep the electric needle at the acupoint for another 3 days.During the needle retention period, the electric needles at the bilateral ovarian acupoints and bilateral waist and eye acupoints were alternately stimulated once every other day using an electroacupuncture device for 30 minutes each time.

  • Otherplacebo electro-thumbtack needle

    The control group selected acupoints that were the same as the treatment group. Bilateral ovarian acupoints and bilateral waist and eye acupoints are treated with placebo electro-thumbtack needle, while other acupoints are treated with placebo electro-thumbtack needle. The treatment methods for placebo electro-thumbtack needle and placebo thumbtack needle are the same as those for the treatment group.

06

What researchers measure

Primary outcomes

  1. live birth rate

    The live birth rate is defined as the proportion of live births after 28 weeks of pregnancy, usually calculated by dividing the number of live birth cycles by the total number of patients and multiplying by 100%. This indicator is commonly used to evaluate the effectiveness of reproductive health centers or specific treatment methods, reflecting the ultimate outcome of successful pregnancy.

    Time frame: 3 months

Secondary outcomes

  1. Biochemical pregnancy rate

    Biochemical pregnancy, also known as subclinical miscarriage or occult miscarriage, refers to the phenomenon where the embryo fails to successfully implant on the uterine wall in the early stages, leading to termination of pregnancy.The biochemical pregnancy rate is calculated by dividing the number of biochemical pregnancies by the total number of patients.

    Time frame: 3 months

  2. clinical pregnancy rate

    Clinical pregnancy refers to the presence of a gestational sac in the uterine cavity, as well as the appearance of fetal buds and primitive heartbeats, observed through ultrasound examination in the early stages of pregnancy. These signs indicate normal implantation and development of the embryo, confirming a normal intrauterine pregnancy.The clinical pregnancy rate is calculated by dividing the number of pregnancies by the total number of patients.

    Time frame: 3 months

  3. Threatened miscarriage rate

    Threatened miscarriage refers to symptoms such as vaginal bleeding and abdominal pain that occur before 28 weeks of pregnancy, but at this time the cervix is not open, the membranes are intact, there is no discharge of pregnancy material, and the size of the uterus matches the gestational age. The threatened miscarriage rate is calculated by dividing the number of threatened miscarriages by the total number of patients.

    Time frame: 3 months

  4. abortion rate

    The miscarriage rate is calculated by dividing the number of miscarriages by the total number of patients.

    Time frame: 3 months

  5. Anti Mullerian hormone (AMH)

    Anti Mullerian hormone (AMH) is a glycoprotein hormone secreted by follicular granulosa cells in the ovary. It is of great significance in evaluating women's ovarian reserve function and can be used to assess the number and quality of follicles in the ovaries. The concentration of AMH in serum will be measured.

    Time frame: 3 months

  6. Antral Follicle Count (AFC)

    Antral Follicle Count (AFC) refers to the count of antral follicles present in the ovary using ultrasound technology. Sinus follicles are small follicles with a diameter of approximately 2-9mm located in the ovary. These follicles are in the early developmental stage of the cycle and have a good correlation with women's ovarian reserve function

    Time frame: 3 months

  7. follicle stimulating hormone(FSH)

    The concentration of follicle stimulating hormone(FSH) in serum will be measured. The changes in FSH levels can reflect ovarian function and ovulation status, and are of great significance for the diagnosis and monitoring of various gynecological diseases.FSH was measured on the second day of menstruation.

    Time frame: 3 months

  8. Luteinizing hormone (LH)

    The concentration of Luteinizing hormone (LH) in serum will be measured. LH is a glycoprotein hormone secreted by pituitary cells, mainly acting on mature oocytes, which can induce ovulation and produce corpus luteum.LH is measured on the second day of menstruation.

    Time frame: 3 months

  9. estradiol(E2)

    The concentration of estradiol(E2) in serum will be measured.The level of estradiol is commonly used to assess the reproductive health status of women, which is measured on the second day of menstruation.

    Time frame: 3 months

  10. Progesterone(P)

    The concentration of Progesterone(P) in serum will be measured.Progesterone is an important progesterone mainly secreted by the corpus luteum of the ovary and also present in the adrenal cortex and placenta. Progesterone plays a crucial role in the female reproductive system, including maintaining normal menstrual cycles, promoting endometrial development, providing a suitable implantation environment for fertilized eggs, and maintaining pregnancy.

    Time frame: 3 months

  11. Prolactin(PRL)

    The concentration of Prolactin(PRL) in serum will be measured.Prolactin also affects female reproductive function, such as follicle development and ovulation process

    Time frame: 3 months

  12. Testosterone(T)

    The concentration of Testosterone(T) in serum will be measured.Testosterone is a steroid hormone mainly secreted by the testicles of males and ovaries of females

    Time frame: 3 months

  13. ZungSelf-RatingAnxietyScale(Zung-SAS)

    Zung SAS is mainly used to evaluate an individual's anxiety symptoms and their severity.The total score range of this scale is 20 to 80 points. After conversion, the score can be used as an indicator of anxiety level - usually multiplying the original score by 1.25 and converting it into a norm score. The higher the norm score, the more severe the individual's anxiety level.

    Time frame: 3 months

  14. Zung Self-rating depression scale(Zung-SDS)

    Zung SDS is mainly used to evaluate the severity and changes of individual depressive symptoms.Composed of 20 questions, the scores of each of the 20 items are added together to obtain a rough score. The standard score is equal to the integer part obtained by multiplying the coarse score by 1.25. The normal upper limit of the total gross score is 41 points, and the standard total score is 53 points.

    Time frame: 3 months

  15. Short form-36(SF-36)

    SF-36, The Medical Outcomes Study - Short Form, also known as the Health Survey Short Form, is a universal measurement scale developed from the Boston Health Study in the United States. This scale consists of 36 items and is evaluated.The score range of SF-36 scale is 0-100 points, where 100 points represents the best health status and 0 points represents the worst health status.

    Time frame: 3 months

  16. Chinese Quality of Life Scale (CHQOL)

    The Chinese Quality of Life Scale (CHQOL) is a new universal scale developed based on the concept of traditional Chinese medicine health, which is used for evaluation.Full score of 60, the higher the score, the higher the quality of life.

    Time frame: 3 months

  17. Self Rating Sleep Scale (SRSS)

    SRSS is a tool used to screen and evaluate individual sleep problems. It consists of 10 items, each rated on a 5-point scale, with higher scores indicating more severe sleep problems. The scoring criteria for the SRSS are as follows: 10 items are rated on a scale of 1-5, with a total score range of 10-50 points. The higher the score, the more severe the sleep problem.

    Time frame: 3 months

  18. The Sleep Disorders Rating Scale (SDRS)

    The Sleep Disorders Rating Scale (SDRS) is a tool used to assess an individual's sleep status over the past week.Each item has a maximum score of 3 points, and the total score can reach up to 21 points. The higher the score, the more severe the sleep disorder.

    Time frame: 3 months

  19. Pittsburgh Sleep Quality Index (PSQI)

    The Pittsburgh Sleep Quality Index (PSQI) is a widely used self-assessment scale used to evaluate an individual's sleep quality over the past month.The total score range of the scale is 0-21 points, with higher scores indicating poorer sleep quality.

    Time frame: 3 months

  20. corticotropin releasing hormone (CRH)

    The concentration of CRH in serum will be measured.Corticotropin releasing hormone (CRH) is a forty one peptide hormone secreted by the hypothalamus. Its main function is to promote the synthesis and release of adrenocorticotropic hormone (ACTH) by the pituitary gland, thereby regulating the secretion of glucocorticoids by the adrenal cortex

    Time frame: 3 months

  21. norepinephrine

    The concentration of norepinephrine in serum will be measured.

    Time frame: 3 month

  22. epinephrine

    The concentration of epinephrine in serum will be measured.

    Time frame: 3 months

  23. 5-hydroxytryptamine (5-HT)

    The concentration of 5-hydroxytryptamine (5-HT) in serum will be measured.

    Time frame: 3 months

  24. gamma aminobutyric acid (GABA)

    The concentration of gamma aminobutyric acid (GABA) in serum will be measured.

    Time frame: 3 months

  25. dopamine (DA)

    The concentration of dopamine (DA) in serum will be measured.

    Time frame: 3 months

  26. beta endorphin (β - ET)

    The concentration of beta endorphin (β - ET) in serum will be measured.

    Time frame: 3 months

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for May 2027; primary completion for May 2030, 36 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: start Oct 2025 → May 2027, primary completion Oct 2029 → May 2030 and completion Oct 2029 → May 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2025
First posted
Aug 26, 2025
StartEst.
May 30, 2027was Oct 2025
Primary completionEst.
May 30, 2030was Oct 2029
CompletionEst.
May 30, 2031was Oct 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2025→May 30, 2027
Nov 17, 2026
Primary completion
Oct 30, 2029→May 30, 2030
Nov 17, 2026
Study completion
Oct 30, 2029→May 30, 2031
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Start date Oct 1, 2025→May 30, 2027
    Primary completion Oct 30, 2029→May 30, 2030
    Study completion Oct 30, 2029→May 30, 2031
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07142187
Responsible party
Dongmei Huang (Clinical Professor of Integrated Traditional Chinese and Western Medicine at Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Tongji Hospital) — Principal investigator
First posted
Aug 26, 2025
Start date
May 30, 2027 (estimated)
Primary completion
May 30, 2030 (estimated)
Completion
May 30, 2031 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion